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Background: Precision-cut liver slices present different cell types of liver in a physiological context, and they have
been explored as effective in vitro model systems to study liver fibrosis. Inducing fibrosis in the liver slices using
toxicants like carbon tetrachloride is of less relevance to human disease conditions. Our aim for this study was to
establish physiologically relevant conditions in vitro to induce fibrotic phenotypes in the liver slices.
Results: Precision-cut liver slices of 150 μm thickness were obtained from female C57BL/6 J mice. The slices were
cultured for 24 hours in media containing a cocktail of 10 nM each of TGF-β, PDGF, 5 μM each of lysophosphatidic
acid and sphingosine 1 phosphate and 0.2 μg/ml of lipopolysaccharide along with 500 μM of palmitate and were
analyzed for triglyceride accumulation, stress and inflammation, myofibroblast activation and extracellular matrix
(ECM) accumulation. Incubation with the cocktail resulted in increased triglyceride accumulation, a hallmark of
steatosis. The levels of Acta2, a hallmark of myofibroblast activation and the levels of inflammatory genes (IL-6,
TNF-α and C-reactive protein) were significantly elevated. In addition, this treatment resulted in increased levels of
ECM markers - collagen, lumican and fibronectin.
Conclusions: This study reports the experimental conditions required to induce fibrosis associated with steatohepatitis
using physiologically relevant inducers. The system presented here captures various aspects of the fibrosis process like
steatosis, inflammation, stellate cell activation and ECM accumulation and serves as a platform to study the liver fibrosis
in vitro and to screen small molecules for their antifibrotic activity.
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Liver fibrosis is a pathological condition that results due
to progressive accumulation of extracellular matrix in
the liver. Several etiological factors like viral infection,
alcohol abuse, insulin resistance and metabolic disorder
contribute to the development of fibrotic phenotype [1].
It is a complex process involving various cell types of
liver including hepatocytes, several immune cell types
and stellate cells [2,3]. Following an initial injury to
the liver (mainly to hepatocytes), the hepatic stellate
cells get activated and differentiate into myofibroblasts,* Correspondence: anup.oommen@connexios.com;
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unless otherwise stated.acquiring a pro-inflammatory and fibrogenic properties
[4], and this event coupled with several other dysregula-
tions leads to excess production of extracellular matrix
(ECM). Uncontrolled liver fibrosis can eventually lead to
total liver failure and it is one of the top 10 causes of
mortality in the western world [5]. An effective cure for
liver fibrosis is not available yet, and part of the reason for
the slow progress of the pharmaceutical industry in this
direction is lack of an effective in vitro model system to
screen the small molecules [6,7]. Several research groups
are working toward mechanisms underlying the deve-
lopment of disease and to identify potential antifibrotic
compounds. The success of these studies would greatly
depend on employing a suitable model system that cap-
tures various aspects of liver fibrosis as motioned above.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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model systems to address mechanism-based questions
and to understand the cell type-specific biology. However,
they fail to represent the liver as a multicellular system in
which several cell types and cell-cell interactions contri-
bute toward fibrogenesis [5]. Precision-cut liver slices have
recently been evaluated for their use in studies with liver
fibrosis [8-10], and they are more promising as model
systems when compared to cell line-based systems. One
major advantage of employing them as a model system is
that they present several cell types of liver in a physio-
logical milieu and they retain crucial interactions between
different cell types and between cells and their ECM.
Earlier studies have used carbon tetrachloride (CCL4)
as an inducer of liver fibrosis in a liver slice model sys-
tem. CCL4 captures several endpoints involved in liver
fibrosis, and is one of the oldest toxins known to stimu-
late fibrotic phenotype in the liver. However CCL4 is a
nonphysiological challenge, and it has no etiological
significance in human disease [11] but only leads to bio-
chemical and histological changes similar to those of hu-
man disease condition [12]. Liver slices prepared from
the rats with established fibrosis is a more physiolo-
gically relevant model, and this system has been used for
screening antifibrotic compounds [8,13]. However, de-
veloping this model system can be time consuming, re-
quiring about 3 to 4 weeks for the animals to develop
disease.
In the present study, we report on developing liver
fibrosis in liver slices using physiological signals that will
activate key signaling pathways effectively and finally
result in important end points relevant to NAFLD/fibrosis -
triglyceride accumulation, hepatocyte dysfunction and
inflammation, hepatic stellate cell activation, and ECM
remodeling with increased collagen production.
Results and discussion
Several signaling pathways are activated during patho-
genesis of fibrosis, and each of these pathways contrib-
utes at various stages of the pathology finally leading to
hepatic stellate cell activation and ECM production. The
key pathways that contribute can be broadly categorized
into inflammatory pathway, growth factor signaling and
lipid signaling pathway. Most important among these
pathways are the inflammatory pathway and the growth
factor signaling mediated by TGF-β and PDGF sig-
naling [2,10].
TGF-β is one of the potent inducers of fibrogenesis
[14]. It plays a major role in the transformation of he-
patic stellate cells into myofibroblasts and stimulates the
synthesis of extracellular matrix proteins while inhibiting
their degradation [15]. TGF-β signaling pathways have
been explored as a target for fibrosis therapy [16]. PDGF
is another potent proliferative factor for hepatic stellatecells and myofibroblasts during liver fibrogenesis [17].
During the process of fibrogenesis, it is secreted by a va-
riety of cell types such as hepatocytes, kupffer cells and ac-
tivated hepatic stellate cells, and many pro-inflammatory
cytokines mediate their mitogenic effects via the autocrine
release of PDGF [17].
Sphingosine 1 phosphate is well known for its diverse
biological roles [18]. In the context of tissue fibrosis, S1P
influences various aspects of fibroblast migration, stellate
cell activation, myofibroblast differentiation and vas-
cular permeability [19]. Several studies have established
a causal connection between S1P and fibrosis of various
organs like liver, lung and heart [20-22].
Phospholipid growth factors like lysophosphatidic acid
(LPA) are known for their growth factor-like activity
[23,24]. LPA exerts its action through well-characterized
membrane receptors and has been found to promote cell
division and migration and to inhibit apoptosis [25].
Relevant to fibrosis, LPA is shown to facilitate myofibro-
blast differentiation and ECM generation through activa-
tion of Rho-ROCK pathway [26,27].
Lipopolysaccharides (LPS), the cell wall derivatives of
gram negative bacteria, activate toll-like receptor (TLR)
pathways. The TLRs are expressed on variety of liver cell
types that are central to the process of fibrosis like hepa-
tocytes, kupffer cells and HSCs [28]. TLR pathways play
critical role in fibrogenesis [28,29].
In order to activate the signaling pathways discussed
above, we formulated a cocktail containing 10nM each
of TGF-β, PDGF, 5 μM each of lysophosphatidic acid
and sphingosine 1 phosphate, and 0.2 μg/ml of lipopoly-
saccharide, along with 500 μM of palmitate. Palmitate
was incorporated in the cocktail to facilitate lipid accu-
mulation in the liver slices. We refer to this cocktail as
IGL cocktail (denoting inflammatory, growth factor and
lipid mediator). Viability of liver slices was estimated as
a measure of total ATP content of the slices. Liver slices
retained significant viability during the treatments for up
to 24 hours as indicated in Figure 1. However, when ex-
tended up to 48 hours, the viability of the control and
the cocktail treated slices declined to about 64% and
60% of the initial value, respectively. Most notably, the
CCL4 treatment for 48 hours resulted in a drastic reduc-
tion in viability, with the treated slices showing only
about 43% viability. This might be due to the more pro-
nounced toxic effects of CCL4, when compared to those
of the IGL cocktail.
An inflammatory, growth factor and lipid mediator
cocktail (IGL) system captures the aspects of steatosis and
inflammation
Development of liver fibrosis associated with NASH
(nonalcoholic steatohepatitis) can be explained by two
































Figure 1 Viability of liver slices. Liver slices of 150 μm thickness
were obtained and incubated with Williams E media supplemented
with 15% fetal bovine serum and 1% GlutaMAX for indicated time
periods. ATP levels were estimated at the end of the experiment,
and levels were normalized to total protein content. The ATP levels
in the control slices (incubated for 4 hours) were normalized to 100
and the percent ATP levels were calculated accordingly. **P <0.01
and ***P <0.001, when compared to respective samples at 4 hours.
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atocyte injury, inflammation and fibrosis [30,31]. Contrary
to the initial belief that fat accumulation in the liver is a
benign condition, several studies have established hepatic
fat storage as a risk factor for the progression of hepatic
fibrosis [32]. Triglyceride (TG) accumulation and lipid
droplet formation tightly correlate with pathophysiological
mechanisms in NASH [33] and TG accumulation is a po-
tent trigger for hepatocytes injury and inflammation. In
our assay system we tested the levels of triglycerides.
When treated with IGL cocktail, the liver slices showed
increased triglyceride accumulation (Figure 2A). CCL4
treatment under similar conditions did not result in any
change in the triglyceride levels.
Increased inflammation in these slices was evident
with increased expression levels of CRP, IL6 and TNF-α
(Figure 2B, C and D) following treatment with the IGL
cocktail. CRP is a well-known marker of inflammation
and is also proposed as a marker of nonalcoholic fatty
liver disease [34,35]. Animal model and clinical studies
indicate that TNF-α is involved in mediating both initial
and advanced stages of liver damage [36]. IL-6 is a pleio-
tropic inflammatory cytokine and is involved synthesis
of broad spectrum of acute phase proteins, chronic in-
flammation and fibrogenesis [37]. Monocyte chemo-
attractant protein 1 (MCP-1) plays an important an role
in inflammation, liver injury and NASH [38,39] and is
used as a reliable marker for inflammation. However, in
our study, MCP-1 levels did not significantly increase fol-
lowing treatment, either with the IGL cocktail or CCL4
(Figure 2E). The reason behind this could be kinetics of
expression of MCP-1 during the process of in vitro fibrosis(as in the current study), and we speculate that MCP-1 ex-
pression is a very early event during fibrosis. This is fur-
ther supported by a study that reports that following
CCL4 treatment rat liver shows increased expression of
MCP-1 between 6 to 48 hours, but is not detectable after
60 hours [38]. Oxidative stress is known to significantly
contribute to fibrogenesis, and reactive oxygen species
and the lipid peroxides are shown to enhance inflamma-
tion and cellular damage, stellate activation and produc-
tion of collagen [40-42]. To assess if the IGL cocktail
treatment influences the oxidative stress in the slices, we
estimated the oxidative stress in the liver slices. As shown
in the Figure 2F, the IGL cocktail treatment resulted in
about a 50% increase in oxidative stress levels. CCL4 treat-
ment, in comparison, had higher levels of oxidative stress
compared to the cocktail treatment.Inflammatory, growth factor and lipid mediator cocktail
treatment results in stellate cell activation
Stellate cell activation is a key event in liver fibrosis, and it
involves the process of transition of a quiescent, adipose-
like vitamin-A storing cell to a highly fibrogenic cell [41].
Upon activation, stellate cells undergo a programmed cas-
cade of events to differentiate into myofibroblasts. Myofi-
broblasts are more motile and contractile in nature, and
this functional transition is paralleled with an increased
expression of Acta2 [43,44]. We assessed the expression of
this gene following exposure to IGL cocktail. As shown in
the Figure 3A, with IGL treatment, the levels of Acta2
were increased appreciably. αB-crystallin is small heat
shock protein belonging to the HSP20 family, and it is
known to protect the cells against protein degradation. It
is implicated as a marker for early hepatic stellate cell acti-
vation [45]. Following treatment with IGL cocktail the
levels of αB-crystallin were found to be upregulated in the
liver slices (Figure 3B). Desmin is an intermediate filament
typical of contractile cells and is used as a gold standard
for stellate cell activation [9,46]. Upon stimulation by IGL
cocktail, the levels of desmin increased in the liver slices
as indicated in Figure 3C.Inflammatory, growth factor and lipid mediator cocktail
system captures the aspects of extracellular matrix
accumulation and remodeling
An imbalance between ECM synthesis and degradation
leads to excessive ECM accumulation, an end point that
defines liver fibrosis. To evaluate if the treatment with the
IGL cocktail resulted in fibrogenesis, collagen content was
estimated in the liver slices. Collagen is a major protein
constituent of the ECM. As indicated in Figure 4A and B,
the collagen content of the liver slices was significantly
increased following treatment with the IGL cocktail. In





































































































































Figure 2 Steatosis, inflammation and oxidative stress in the liver slices cultured in the inflammatory, growth factor and lipid mediator
(IGL) cocktail. Liver slices of 150-μm thickness were cultured either with CCL4 or IGL cocktail for 24 hours, after which triglyceride levels (A) and
oxidative stress levels (F) were estimated. RNA was isolated from the liver slices, and expression levels of CRP (B), IL-6 (C), TNF-α (D) and MCP-1
(E) were quantified by real-time quantitative PCR using the beta actin gene as the endogenous control. Expression levels of each of the genes in
the control samples (liver slices cultured with culture media alone without CCL4 or IGL cocktail) were normalized to 1. Values represent mean ± SEM
(n = 4 per group). An unpaired student t-test was used for statistical comparison. *P <0.05, **P <0.01, and ***P <0.001, when compared to control.
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to treatment with the IGL cocktail (Figure 5).
PAI-1 is an inhibitor of serine protease tissue plas-
minogen activator (tPA) and urokinase (uPA) and is a
potent inhibitor of fibrinolytic activity. Increased levels
of PAI-1 are correlated with fibrogenesis [47]. While
increased synthesis of collagen contributes to ECM ac-
cumulation, inhibition of uPA and tPA resulting from
elevated PAI-1 sustains the fibrosis [48]. Increases in the
PAI-1 levels were seen upon treatment with IGL cocktail
(Figure 6A). In addition to PAI-1, studies have identified
that TIMPs (tissue inhibitor of metalloproteinases) play
a key role in the fibrosis and a correlation betweenTIMP levels, and fibrosis has been established in a rat
model of liver fibrosis [49]. As indicated in Figure 6B,
TIMP1 levels were significantly increased in response to
treatment with the cocktail. CCL4 treatment, however,
did not result in appreciable changes in the levels of
either PAI-1 or TIMP1. HSP47 is a heat-shock protein
expressed mainly by the myofibroblasts, and it acts as a
molecular chaperone for procollagen molecules. This
function of HSP47 results in stabilization of collagen
molecule, an important ECM protein whose levels are
increased in the fibrosis. The level of HSP47 has been
shown to be upregulated in the animal models of liver



































































Figure 3 Effect of the inflammatory, growth factor and lipid mediator (IGL) treatment on the hepatic stellate cell activation. Liver slices
of 150-μm thickness were cultured either with CCL4 or IGL cocktail for 24 hours and expression levels of Acta2 (A), αB-crystallin (B) and desmin
(C) were quantitated by real-time quantitative PCR using the beta actin gene as an endogenous control. Expression levels of each of the genes in
the control samples (liver slices cultured with culture media alone without CCL4 or IGL cocktail) were normalized to 1. Values represent mean ± SEM
(n = 4 per group). An unpaired student t-test was used for statistical comparison. *P <0.05, **P <0.01, and ***P <0.001, when compared to control.
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levels of HSP47 were increased following treatment with
the cocktail as indicated in Figure 6C.
Conclusions
Our assay system indeed captures critical aspects of
the pathology-like inflammation and oxidative stress,






























Figure 4 Effect of inflammatory, growth factor and lipid mediator (IG
cultured either with CCL4 or IGL cocktail for 24 hours, and the expression le
the beta actin gene as an endogenous control (A). Expression levels of eac
media alone, without CCL4 or IGL cocktail) were normalized to 1. Total coll
represent mean ± SEM (n = 4 per group). An unpaired student t-test was used
to control.overproduction. Although this cocktail is not exhaustive
in representing all the signaling pathways, it neverthe-
less corresponds to diverse arms of signaling networks
involved in fibrogenesis. The fact that the IGL cocktail
treatment results in a steatotic phenotype in the slices
as measured in terms of triglyceride accumulation
makes it very suitable for use in studying fibrosis in the
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Figure 5 Effect of inflammatory, growth factor and lipid mediator treatment on extracellular matrix (ECM) accumulation. Liver slices of
150 μm thickness were cultured either with CCL4 or IGL cocktail for 24 hours and the expression levels of Lumican (A), Fibronectin (B) and
Fibulin2 (C) were quantitated by real-time quantitative PCR using the beta actin gene as an endogenous control. Expression levels of each of the
genes in the control samples (liver slices cultured with culture media alone without CCL4 or IGL cocktail) were normalized to 1. Values represent



































































Figure 6 Effect of inflammatory, growth factor and lipid mediator (IGL) treatment on extracellular matrix (ECM) remodeling. Liver slices
of 150-μm thickness were cultured either with CCL4 or IGL cocktail for 24 hours and expression levels of PAI-1(A), TIMP1(B) and HSP47 (C) were
quantitated by real-time quantitative PCR using beta actin gene as endogenous control. Expression levels of each of the genes in the control
samples (liver slices cultured with culture media alone without CCL4 or IGL cocktail) were normalized to 1. Values represent mean ± SEM (n = 4
per group). An unpaired student t-test was used for statistical comparison *P <0.05, **P <0.01, and ***P <0.001, when compared to control.
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Table 1 Sequences of the primers used in this study
Gene Primer
CRP Forward TGG TGG GAG ACA TCG GAG AT
Reverse GCC CGC CAG TTC AAA ACA TT
IL6 Forward CTG ATG CTG GTG ACA ACC AC
Reverse CAG AAT TGC CAT TGC ACA AC
TNF-α Forward TAG CCA GGA GGG AGA ACA GAA A
Reverse CCA GTG AGT GAA AGG GAC AGA A
ACTA2 Forward GCCAGTCGCTGTCAGGAACCC
Reverse: GCGAAGCCGGCCTTACAGAGC
αB-Crystallin Forward TTC TTC GGA GAG CAC CTG TT
Reverse CCC CAG AAC CTT GAC TTT GA
Collagen (Col1a1) Forward ATG GCC AAC CTG GTG CGA AAG G
Reverse ACC AAC GTTA CCA ATG GGG CCG
Lumican Forward TGC AGT GGC TCA TTC TTG AC
Reverse GGA CTC GGT CAG GTT GTT GT
Fibulin 2 Forward GAA CTT CTC GGA TGC TGA GG
Reverse CAA CTG GCC AGG GTG TTA CT
PAI-1 Forward CAG CCC TTG CTT GCC TCA T
Reverse CCG AGG ACA CGC CAT AGG
MCP-1 Forward AGC ACC AGC CAA CTC TCA CT
Reverse TCA TTG GGA TCA TCT TGC TG
HSP47 Forward GTT TCT TGG GAC AGG CAG GAG
Reverse GCC TGC CTT TTT CAT TCT GGG C
Desmin Forward TCG CGG CTA AGA ACA TCT CT
Reverse TCG GTA TTC CAT CAT CTC CTG
Sadasivan et al. Fibrogenesis & Tissue Repair  (2015) 8:1 Page 7 of 9that this system does not represent progression of fibro-
sis pathology from steatosis to steatohepatitis and fibro-
genesis, in which case one would expect development of
fibrogenesis in the slices following incubation with
palmitic acid alone. We feel that this would not be practic-
ally possible in a liver slice system given that progression
from steatosis to fibrosis requires a long time, at least
in vivo [51], and translating this in an ex vivo set-up such
as liver slice may be limited due to viability issues. Never-
theless, triglyceride accumulation in the slices sets up a
suitable background of steatosis that contributes to key as-
pects of liver fibrosis.
Methods
Materials
The William’s E Media, GlutaMAX, fetal bovine serum for
the cell culture, ATP estimation kit, recombinant TGF-β
and the PDGF were purchased from Life Technologies
USA. Lysophosphatidic acid, lipopoly saccharide and pal-
mitic acid were purchased from Sigma Aldrich. The cDNA
synthesis kit was from BioRad, the qPCR kit was from
KAPA Biosystems, and the triglyceride estimation kit
(TAG reagent) was from Diasys.
Animals
C57BL/6 J female mice were housed at 22 ± 3°C, with a
relative humidity of 50 to 70% on a 12 h light and 12 h
dark cycle with artificial fluorescent tubes. Animals were
fed ad libitum with normal chow diet. Mice aged bet-
ween 8 to 12 weeks were used for preparation of liver
slices. In order to minimize any possible variations em-
anating from sex differences, only female mice were
used throughout the study. The study protocol, animal
maintenance, and experimental procedures were all ap-
proved by the Institutional Animal Ethics Committee
(IAEC) of Connexios Life Sciences, which is approved by
CPCSEA (Committee for the Purpose of Control and
Supervision of Experiments on Animals, government of
India).
Preparation of liver slices
Williams E media was prepared with 15% FBS and 1%
GlutaMAX. Five milliliters of media was dispensed to
each T25 flask. 8 to 12 week old C57BL/6 J animals were
euthanized using isoflurane, and the liver was collected
in a Petri dish containing pre-warmed Williams E media
The lobes of the liver were separated and were cut into
small pieces of about 10 mm3. Precision-cut liver slices
of 150 μm thickness was obtained using automated vibra-
ting blade microtome (Leica VT 1200S), and the slices
were collected under aseptic conditions into pre-warmed
media. About 8 to 10 precision-cut liver sections were
then distributed to each T25 flask on a random basis. The
thickness of the liver slices influences the viability of thecells and oxygen diffusion during incubations [5]. Using
the slices of greater thickness would result in reduced oxy-
gen diffusion into the slices, while using slices of lesser
thickness can affect the viability of the cells in the outer
layer of the slices. In literature people have successfully
used thicknesses as low as 100 μm [52] and also the slices
up to about 250 μm [5]. In the current study, we use slices
of 150-μm thickness, and this thickness was good enough
to retain viability of the slices for up to 24 hours as dis-
cussed in results section.
Liver slice culture
Liver slices from mouse (8- to 12-week-old C57BL/6 J)
were cultured in William’s E Media supplemented with
15% Fetal Bovine serum (FBS) and 1% GlutaMAX [10].
Cultures were maintained in a humidified atmosphere of
95% air and 5% CO2 at 37°C. In order to induce a fi-
brotic phenotype, the slices were cultured for 24 hours
in the media with a cocktail containing 10nM each of
TGF-β, PDGF, 5 μM each of lysophosphatidic acid and
sphingosine 1 phosphate and 0.2 μg/ml of lipopolysac-
charide. Where mentioned, CCL4 was used at a concen-
tration of 0.1%.
Sadasivan et al. Fibrogenesis & Tissue Repair  (2015) 8:1 Page 8 of 9Quantitative real-time PCR
Total RNA was isolated from each liver slice using TRIZOL
(Ambion), and 1 μg of RNA was reverse-transcribed with
the iScript cDNA synthesis kit (BIO RAD). The qRT-PCR
assays were performed in 10-μl reactions containing
1× SYBR Green Master Mix buffer (KAPA), and 300 nM
gene-specific primers. Assays were performed using a
CFX96 Real-Time System (Bio-Rad Laboratories). Samples
were incubated in SYBR Green Master Mix for an initial
denaturation at 95°C for 3 min, after which 40 PCR cycles
were performed, with each cycle consisting of 95°C for
10 s, 60°C for 10 s and 72°C for 15 s. Amplification of spe-
cific transcripts was confirmed by melting curve profiles
(cooling the sample to 68°C and heating slowly to 95°C
with measurements of fluorescence) at the end of each
PCR. Each gene expression was calculated relative to beta
actin gene, which was used as an internal control by using
the ΔΔCT analysis method. The primer sequences are
listed in Table 1.
Triglyceride estimation
Liver slices were bead lysed in 100 μl lysis buffer ( 50 mM
Tris, 150 mM NaCl, 0.1% Triton X 100, pH 7.4), at 25 Hz
for 5 minutes. The lysed samples were centrifuged at
10,000 rpm for 10 minutes, and the supernatant was taken
for analysis. Next, 200 μl of TAG reagent (Triacyl glycerol
reagent, supplied with the kit) was added to 10 μl of the
sample or standard and incubated at 37°C for 10 min and
absorbance was read at 500 nm. The TAG was normalized
to total cellular protein.
Soluble collagen estimation
Liver slices were bead lysed in 100 μl lysis buffer ( 50 mM
Tris, 150 mM NaCl, 0.1% Triton X 100, pH 7.4) at 25 Hz
for 5 minutes. The lysed samples were centrifuged at
10,000 rpm for 10 minutes and the supernatant was taken
for analysis. Next, 200 μl of Sirius red dye was added to
40 μl of sample and incubated at room temperature for
2 h. The samples were centrifuged at 12,000 rpm for
15 minutes. The pellet was washed with 500 μl of phos-
phate buffered saline (PBS) and then with 500 μl of 0.05 N
hydrochloric acid. Pellet was dissolved in 100 μl of 0.2 N
Sodium hydroxide and absorbance read at 540 nm. The
collagen levels were normalized to total cellular protein
content.
Assay for viability
Immediately following termination of the experiment,
liver slices were lysed in 100 μl lysis buffer (0.1 N NaOH,
0.1% Triton X100). The samples were centrifuged at
10,000 rpm for 10 minutes, and the supernatant was used
for estimation of ATP using ATP determination kit fol-
lowing manufacturer’s instructions (Life Technologies).Abbreviations
ECM: extracellular matrix; IL-6: interleukin-6; PDGF: platelet derived growth
factor; TAG: triacyl glycerol; TG: triglcyerides; TGF-β: transforming growth
factor beta; TNF-α: tumor necrosis factor alpha.
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